Physician profile
Daniel Leon Rivera
NPI 1104530914
$2,870.53
in general payments reported to CMS, 2019-2025
11 companies · $913 in 2025
The $913 reported for 2025 was more than what 79% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $616 · 2024: $1,341 · 2025: $913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,871.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,870.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $550.27 | 2023-2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $530.76 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Otsuka America Pharmaceutical, INC. | $330.27 | 2023-2025 | Rexulti, Nuedexta |
| Sanofi-Aventis U.S. LLC | $317.81 | 2024 | |
| Abbvie INC. | $306.34 | 2023-2024 | |
| Janssen Pharmaceuticals, INC | $241.36 | 2025 | Invega Sustenna |
| Alkermes, INC. | $155.17 | 2023-2024 | Lybalvi, Vivitrol |
| Corium, LLC | $125.00 | 2023 | Azstarys |
| Neurocrine Biosciences, INC. | $118.80 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $102.64 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $92.11 | 2024 | Cobenfy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.